Revolutionizing the Diagnosis of Life-altering Diseases 為重疾診斷技術帶來革命性突破 | VolitionRx (NYSE-A: VNRX)

We are pleased to invite our old friend, Scott Powell, EVP and Head of IR of #VolitionRx Limited (NYSE AMERICAN: VNRX), to join us for an updated interview. Scott elaborated on the company's recent clinical study results on cancer #diagnosis . Besides, he talked about a recent capital raising of over 19 million, and new global reach targets in terms of market expansion. The company is transitioning from clinical to commercial stage, and look forward to delivering earnings for the shareholders over the coming years.

Volition will present at our upcoming GCFF 2023 Toronto Conference on Oct 21st.

Free Registration Here! https://gcff-oct-toronto-2023-en.even...

我們很高興再次邀請到我們的老朋友VolitionRx Limited (NYSE AMERICAN: VNRX)的執行副總裁兼投資者關係主管Scott Powell接受我們的採訪。Scott詳細介紹了該公司最近關於癌症診斷的臨床研究結果。此外，他還談到了最近籌集的1900多萬的融資，以及在市場拓展方面的全球布局新目標。公司正從臨床階段向商業階段過渡，並期待在未來幾年為股東帶來收益。

Volition將參加2023年10月21日GCFF多倫多會議並發表演講！

免費註冊連結 https://gcff-oct-toronto-2023-ch.even...

About VolitionRx Limited (NYSE AMERICAN: VNRX)

Volition is a multi-national #epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

Volition’s research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market. For more information. please visit https://volition.com/

關於VolitionRx Limited (NYSE AMERICAN: VNRX)

Volition是一家跨國的表觀遺傳學公司，致力於開發簡單易用和具有成本效益的血液試劑，幫助診斷各種癌症和其他疾病。早期診斷不僅可以延長患者的生命，而且可以改善他們的生活質量。這些測試的基礎NucleosomicsTM科學通常用於在血液或其他體液中鑒定和測量核小體——確定存在疾病。Volition主要側重於人類診斷，也有一個側重於動物診斷的子公司。

Volition的研發活動以比利時為中心，在加利福尼亞州有一個小型實驗室，另外在德克薩斯州、倫敦和新加坡設有辦事處。目前該公司專注於將其診斷產品推向市場。

更多信息，請訪問Volition的網站 http://www.volitionrx.com

Disclaimer: NAI is being compensated for this content. Materials contained in this content are for information purposes only and is not intended to constitute an offering of securities in any jurisdiction. Nothing on this content should be construed as an offer, solicitation or recommendation to buy or sell products or securities.

免責聲明：NAI有償發佈此內容。此內容中所含材料僅供參考，無意構成在任何司法轄區進行證券發行。此內容不應解讀為買賣產品或證券的要約、招攬或推薦。

Music: Envato

【Stay Connected! 持續關注 NAI500!】
Email Subscription: https://sourl.cn/TkSQJk
訂閱郵箱列表：http://eepurl.com/hJorHT
微信公眾號：
GCFF_Event (GCFF會展)；NAI500 (NAI500財經網站)
Website: https://nai500.com
網站：https://nai500.com/zh-hant/
Twitter:   / nai500  
LinkedIn:   / nai-interactive-ltd  
Facebook:   / naigcff  
Join us at an upcoming event! http://www.gcff.ca/
參加我們即將舉行的會展活動！http://www.gcff.cn/

Copyright © 2023 NAI Interactive Ltd. All rights reserved.
版權所有 © 2023 NAI Interactive Ltd. 保留所有權利。